CytRx reports further evidence in support of aldoxorubicin

CytRx (CYTR) is out with more data in support of aldoxorubicin efficacy.

The "additional statistical analyses" of the Phase 2b study determined the hazard ratios on the PFS endpoint: HR for investigator-read scans, 0.37; HR for central lab scans, 0.59.

The company also says a Kaplan-Meier analysis "showed significant improvement in subjects treated with aldoxorubicin versus subjects treated with doxorubicin." (PR)

For the originally reported results, see here.

CYTR +10% premarket

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs